Navigation Links
Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
Date:7/23/2009

LACHEN, Switzerland and HOBOKEN, N.J., July 23 /PRNewswire/ -- Octapharma USA is now accepting applications for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immunotherapy, intensive care and emergency medicine. Applications will be reviewed in October.

Octapharma AG, the third largest plasma products manufacturer in the world, launched the grants program in celebration of its 25(th) anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA, the Swiss company's rapidly-growing U.S. subsidiary.

"We have been committed to patient care and medical innovation since day one and our vision of providing patients with the safest, highest quality human protein therapies available is stronger than ever," said Octapharma USA President Flemming Nielsen. "The Octapharma 25(th) Anniversary Grants Program is our latest initiative to help improve the lives of people around the world."

Grant applications are accepted online only at www.octapharmagrants.com. All grant requests will be evaluated by the Octapharma 25(th) Anniversary Grants Committee in October and the first grants recipients will be announced shortly afterward. Please visit www.octapharmagrants.com for a complete description of the grants program, including the application and review process.

Octapharma AG

Octapharma AG is the third largest plasma products manufacturer in the world and has been committed to patient care and medical innovation for over 25 years. Octapharma's core business is the development, production and sale of high quality human protein therapies, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam(R) (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Based in Lachen, Switzerland, Octapharma employs over 3,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is headquartered in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration, providing the highest level of production flexibility and minimizing product shortages. For more information, please visit www.octapharma.com or call Octapharma USA at 201-604-1130.


'/>"/>
SOURCE Octapharma USA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
3. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
4. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
5. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
6. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
7. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
8. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
9. Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced
10. National Cancer Institute Research Identifies Unique Mechanism of Brostallicins Anti-Tumor Effectiveness
11. UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPars Investigational Cancer Drug BSI-201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017   FormFast , the ... a new partnership with Engage , one of ... States . FormFast will serve as the forms ... implementations with MEDITECH .  FormFast ... functionality to complement and enhance the electronic health record. ...
(Date:2/17/2017)... , February 17, 2017 ... the S&P 500 edged lower at the closing bell, ... streak above the 20,000 benchmark. Moreover, five out of ... Taking into consideration yesterday,s market sentiment, Stock-Callers.com assessed the ... & Nephew PLC (NYSE: SNN ), ABIOMED ...
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... ... Butler Mobility invited Ken Matthews to visit its manufacturing facility and showroom to ... with the safety and reliability of the Stannah Stairlift as well as with the ... by Ken Matthews can be heard on News Radio WHP 580 weekdays from 3:00 ...
(Date:2/18/2017)... ... , ... Park Cities Pet Sitter President, Joette White, has been featured on ... The episode, which was posted this week, features a 30-minute interview of White ... Cities Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s Business ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new ... and contact points to easily connect elderly veterans of America's armed forces to ... funding. It also conveys material on this year's increase in the Veterans Pension ...
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... mobility has not kept pace. Enovate Medical has introduced an innovative workstation designed ... years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network ... prescribing of controlled and non-controlled substances plus the ability to manage orders on ... United States now accept electronic prescriptions, according to the Office of the National ...
Breaking Medicine News(10 mins):